FDA approves ‘game-changing’ pancreatic cancer drug
In a late-stage clinical trial of 500 patients, people who got the drug along with standard chemotherapy lived about twice as long — 13.2 months, on average —…
- Center-left1
- Center2
no rewrites detected — all voices distinct
Summary
In a late-stage clinical trial of 500 patients, people who got the drug along with standard chemotherapy lived about twice as long — 13.2 months, on average — compared with people who got chemotherapy alone. The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque.
Furthermore, The five-year survival rate is only 13%. Revolution Medicines said that more than 2,000 patients have already received Rasonque under an expanded access program that the company started in May. The Food and Drug Administration FDA on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer.
In addition, The drug was approved by the FDA more than six months earlier than expected within a priority review program meant to approve treatments for important public health issues.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
In a late-stage clinical trial of 500 patients, people who got the drug along with standard chemotherapy lived about twice as long — 13.2 months, on average — compared with people who got chemotherapy alone.
reliability moderate2/2 sourcesThe Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
reliability moderate2/2 sourcesThe once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque.
reliability moderate2/2 sources
Reported detailssecondary facts, each attributed to its source
The five-year survival rate is only 13%.
according to Geo NewsRevolution Medicines said that more than 2,000 patients have already received Rasonque under an expanded access program that the company started in May.
according to NBC News — Top StoriesThe five-year survival rate for pancreatic adenocarcinoma — the most common form — is 8%.
according to NBC News — Top StoriesThe Food and Drug Administration FDA on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer.
according to The Hill — Just InThe drug was approved by the FDA more than six months earlier than expected within a priority review program meant to approve treatments for important public health issues.
according to Geo News
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources3 sources cross-checked
Center-left1
Center2
